Cancer Study Participation
Study Participation Information Update
At this time we have taken the difficult decision to suspend recruitment of new cases so that we can allocate all our time and resources to analyzing the samples that have already been submitted.
We are delighted to report that these studies have already led to the development of the following genetic tests.
Detection of canine bladder cancer and canine prostate cancer
We have developed BRAF mutation detection and DNA copy number assays to provide a non-invasive method for early detection, diagnosis and monitoring of canine bladder and prostate cancer – also known as transitional cell carcinoma (TCC) or urothelial carcinoma (UC).
A genetic test that aids distinction between histiocytic malignancies and other round cell neoplasms (eg lymphoma, hemangiosarcoma) that may share similar symptoms and histologic appearance. Sample submission is a cytological smear of aspirated cells or a formalin-fixed paraffin-embedded biopsy specimen.
A genetic test that identifies the presence of a BCR-ABL fusion in canine leukemias, used by veterinarians to determine the likely efficacy of tyrosine kinase inhibitor based therapy. Sample submission requires a heparin blood tube.
A genetic test to predict how long a dog with lymphoma will remain in remission when treated with CHOP chemotherapy. Sample submission is a fine needle aspirate, cytology preparation or formalin-fixed paraffin-embedded biopsy specimen of an affected lymph node, acquired prior to any chemotherapy treatment.
A genetic test to identify aggressive canine mucosal melanoma. Sample submission is a fine needle aspirate, cytology preparation, or formalin-fixed paraffin-embedded biopsy specimen of an oral mass.
Is a genetic test to identify aggressive canine mast cell tumors. Sample submission is a fine needle aspirate, cytology preparation, or formalin-fixed paraffin-embedded biopsy specimen of a mass.